Focused On-demand Library for AN1-type zinc finger protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8TCF1

UPID:

ZFAN1_HUMAN

Alternative names:

Zinc finger AN1-type-containing protein 1

Alternative UPACC:

Q8TCF1; E5RIG0; E5RJ99; Q658R7; Q6IA32; Q6PGQ6; Q9H810

Background:

AN1-type zinc finger protein 1, also known as Zinc finger AN1-type-containing protein 1, plays a crucial role in the regulation of cytoplasmic stress granules (SGs) turnover. These SGs are vital for maintaining cellular protein homeostasis during acute exogenous stress by suspending protein production. The protein associates with SGs, facilitating their arsenite-induced clearance through the recruitment of the ubiquitin-selective ATPase VCP and the 26S proteasome, ensuring efficient degradation of damaged ubiquitinated SG proteins.

Therapeutic significance:

Understanding the role of AN1-type zinc finger protein 1 could open doors to potential therapeutic strategies.